JPMORGAN CHASE & CO - IMMUNOPRECISE ANTIBODIES LTD ownership

IMMUNOPRECISE ANTIBODIES LTD's ticker is IPA and the CUSIP is 45257F200. A total of 29 filers reported holding IMMUNOPRECISE ANTIBODIES LTD in Q3 2021. The put-call ratio across all filers is 0.55 and the average weighting 0.0%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of IMMUNOPRECISE ANTIBODIES LTD
ValueSharesWeighting
Q1 2022$102,000
-90.9%
19,904
-66.9%
0.00%
Q4 2021$1,124,000
+11.8%
60,121
+11.9%
0.00%
Q3 2021$1,005,000
-22.0%
53,720
-22.0%
0.00%
Q2 2021$1,288,000
+196.1%
68,885
+55.4%
0.00%
Q1 2021$435,000
+49.0%
44,320
+127.2%
0.00%
Q4 2020$292,00019,5050.00%
Other shareholders
IMMUNOPRECISE ANTIBODIES LTD shareholders Q3 2021
NameSharesValueWeighting ↓
INGALLS & SNYDER LLC 396,425$5,927,0000.29%
Gradient Capital Advisors, LLC 21,718$325,0000.18%
Hillsdale Investment Management Inc. 15,200$232,0000.02%
Orion Portfolio Solutions, LLC 15,821$237,0000.01%
IFP Advisors, Inc 1,960$30,0000.00%
BANK OF AMERICA CORP /DE/ 300$4,0000.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
CITIGROUP INC 7$00.00%
MORGAN STANLEY 2,100$31,0000.00%
BANK OF MONTREAL /CAN/ 5,900$98,0000.00%
View complete list of IMMUNOPRECISE ANTIBODIES LTD shareholders